NEWARK, Calif., Nov. 1, 2017 /PRNewswire/ -- Protagonist
Therapeutics, Inc. (NASDAQ: PTGX) today announced that Dinesh V. Patel, Ph.D., the company's President
and Chief Executive Officer, will provide a corporate overview at
the Stifel 2017 Healthcare Conference taking place on November 14-15th at the Lotte New York
Palace Hotel in New York, NY.
The Protagonist Therapeutics presentation is scheduled for
Wednesday, November 15 at
10:15 am ET.
A live and archived audio webcast of the presentation can be
accessed by visiting the Investors page of Protagonist Therapeutics
corporate website at http://investors.protagonist-inc.com.
About Protagonist Therapeutics
Protagonist Therapeutics is a clinical development-stage
biopharmaceutical company that utilizes a proprietary technology
platform to discover and develop novel peptide-based drugs to
address significant unmet medical needs. Its primary focus is on
developing potential first-in-class oral targeted therapy-based
peptide drugs that work by blocking biological pathways that are
currently targeted by marketed injectable antibody drugs. Lead oral
peptide candidates, PTG-100 and PTG-200, are based on this
approach. The alfa-4-beta-7 integrin antagonist PTG-100 is
currently in Phase 2b clinical trials for moderate-to-severe
ulcerative colitis, and the company plans to initiate clinical
trials with the interleukin-23 receptor antagonist PTG-200 in 2017
as a potential treatment for Crohn's disease. The company
recently entered into a worldwide license and collaboration
agreement with Janssen Biotech for the clinical development of
PTG-200. Protagonist is also developing an injectable
hepcidin mimetic, PTG-300, for the treatment of rare diseases such
as beta-thalassemia and myelodysplastic syndromes (MDS). PTG-300 is
currently being studied in a Phase 1 clinical trial.
Protagonist is headquartered in Newark, California with pre-clinical and
clinical staff in California, and
discovery operations both in California and Brisbane, Queensland, Australia. For further
information, please visit http://www.protagonist-inc.com.
View original content with
multimedia:http://www.prnewswire.com/news-releases/protagonist-therapeutics-to-present-at-the-stifel-2017-healthcare-conference-300547872.html
SOURCE Protagonist Therapeutics, Inc.